Statins and Prostate Cancer Risk: A Case-Control Study

Shannon, Jackilen; Tewoderos, S.; Garzotto, Mark; Beer, Tomasz M.; Derenick, Rhianna; Palma, Amy; Farris, Paige E.

doi:10.1016/s0022-5347(05)00208-9

Cited by 58 publications

(77 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The main limitations of the observational studies (which were published through 2005) included in the Browning et al metaanalysis (12) include (a) lack of presentation of the results by stage and grade and (b) lack of collection or availability of data on potentially confounding factors beyond simple demographics or on PSA screening history, although many had high quality information on the prescription of statins and other drugs. There is one notable exception, a clinic-based case-control study (15), the study that spurred the recent interest in whether statins specifically influence risk of prostate cancer. The study included detailed information on prescription of statins, potentially confounding factors, and diagnosis of prostate cancer and reported inverse associations with statins for prostate cancer overall, especially with highgrade disease, and decreasing risk with increasing duration of use.…”

Section: Introductionmentioning

confidence: 99%

Epidemiologic Musing on Statin Drugs in the Prevention of Advanced Prostate Cancer

Platz¹

2007

Cancer Epidemiology, Biomarkers &Amp; Prevention

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 99%

Epidemiologic Musing on Statin Drugs in the Prevention of Advanced Prostate Cancer

Platz¹

2007

Cancer Epidemiology, Biomarkers &Amp; Prevention

View full text Add to dashboard Cite

“…However, the findings of the Shannon et al and Graaf et al studies (14,15) could not be replicated and a reduction in overall prostate cancer risk was not seen in four large, prospectively conducted trials (16)(17)(18)34). In three of these four studies, an inverse relationship with advanced prostate cancer was noted for either current or prior statin use, however an overall, decreased prostate cancer risk was not seen.…”

Section: Resultsmentioning

confidence: 95%

Clinical Potential of Statins in Prostate Cancer Radiation Therapy

Hutchinson

Marignol

2017

View full text Add to dashboard Cite

Abstract. Background The management of prostate cancer is a significant healthcare challenge. Many treatment options exist (1-3), with radiation therapy playing a prominent role. However, the morbidity and cost of treatment are not trivial (4, 5). Although risk classification schemes (6) and nomograms (7) attempt to identify men most likely to benefit from treatment, it remains difficult to balance the risks of disease progression against competing risks of mortality (8). This has resulted in controversy over prostate-specific antigen (PSA) screening (9, 10) and possible overtreatment leading to a decreased quality of life (5, 11). Therefore, it is of great interest to conduct research into cancer prevention strategies (12), identification of men who will benefit most from treatment, and effective therapies that limit treatment-related morbidity of prostate cancer.Statins or 3-hydroxyl-3-methylglutaryl-coenzyme A (HMGCoA) reductase inhibitors are widely used medications for hypercholesterolaemia. The demographics of prostate cancer and hypercholesterolaemia overlap. The prevalence of statin use in this older men population is high-approximately 24 million Americans in 2003-2004 (13). Thus, many prostate cancer patients are likely to have already been prescribed statins at the time of their cancer diagnosis and treatment.Initial interest in the use of statins in prostate cancer stemmed from epidemiological studies that investigated their chemopreventive properties. Two large case-control series reported a 50%-65% reduction in overall prostate cancer risk among statin users compared with non-users (14, 15

show abstract

“…20,21 Cox-2 inhibitors Converts arachnoidic acid to prostaglandins which inhibit apoptosis, stimulate cell proliferation and facilitate angiogenesis. 22 Decreased tumour cell proliferation, microvessel density, angiogenesis and HIF-1 and increased apoptosis associated with celecoxib.…”

Section: Statinsmentioning

confidence: 99%

Influence of concurrent medications on outcomes of men with prostate cancer included in the TAX 327 study

Niraula

Pond

Wit

et al. 2013

CUAJ

View full text Add to dashboard Cite

E74Cite as: Can Urol Assoc J 2013;7:E74-E81. http://dx.doi.org/10.5489/cuaj.267. Epub 2011 November 2. AbstractObjectives: The TAX 327 trial was pivotal in establishing docetaxel in castration refractory metastatic prostate cancer. Various commonly prescribed and over-the-counter co-administered medications are thought to exhibit anti-neoplastic properties and/or could potentially have pharmacokinectic interactions with docetaxel lessening the effectiveness of chemotherapy. Methods: To examine the effect of on prostate cancer outcomes within this trial, we examined overall survival, prostate-specific antigen (PSA) response, percent PSA reduction, pain response and QOL responses for 14 families of medications including metformin, digoxin, verapamil, proton pump inhibitors, nitrates, statins, cox-2 inhibitors, warfarin, heparins, ascorbic acid, selenium, tocopherol, antidepressants and erythropoietin. Results: Our findings did not reveal any medication that had a significant additive or synergistic effect with docetaxel. We did note, however, that patients on digoxin or verapamil had poorer overall survival, possibly due to a trend of fewer cycles of administered chemotherapy being administered to the verapamil group, consistent with a pharmacokinectic interaction. Conclusions: These data are only hypothesis-generating given the statistical limitations, but may form a basis for similar future analysis in other malignancies. The data suggest the need to be aware of pharmacokinectic interactions with medications that may interact with docetaxel.

show abstract

Statins and Prostate Cancer Risk: A Case-Control Study

Cited by 58 publications

References 0 publications

Epidemiologic Musing on Statin Drugs in the Prevention of Advanced Prostate Cancer

Epidemiologic Musing on Statin Drugs in the Prevention of Advanced Prostate Cancer

Clinical Potential of Statins in Prostate Cancer Radiation Therapy

Influence of concurrent medications on outcomes of men with prostate cancer included in the TAX 327 study

Contact Info

Product

Resources

About